R Squared’s Travere Therapeutics TVTX Stock Holding History

R Squared’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,050	Closed	-$53.1K	–	1436
2024 Q4	$53.1K	Buy	+3,050	New	+$53.9K	0.05%	477

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

R Squared's TVTX Position: Q1 2025 in Review

R Squared sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 3,050 shares — an estimated $53.1K sold.

R Squared first reported a position in TVTX in Q4 2024 and held it in 1 quarter. The position peaked at $53.1K in Q4 2024. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

R Squared reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 3,050 Travere Therapeutics shares in Q1 2025, an estimated $53.1K.
R Squared first reported a position in Travere Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Travere Therapeutics position peaked at $53.1K in Q4 2024.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.